Fibroblast Growth Factor 23 and αklotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications

Javier A. Neyra, Ming Chang Hu, Orson W. Moe

Research output: Contribution to journalReview articlepeer-review

Abstract

Fibroblast growth factor (FGF) 23 and αKlotho are circulating mineral regulatory substances that also have a very diverse range of actions. Acute kidney injury (AKI) is a state of high FGF23 and low αKlotho. Clinical association data for FGF23 are strong, but the basic pathobiology of FGF23 in AKI is rather sparse. Conversely, preclinical data supporting a pathogenic role of αKlotho in AKI are strong, but the human data are still being generated. This pair of substances can potentially serve as diagnostic and prognostic biomarkers. FGF23 blockade and αKlotho restoration can have prophylactic and therapeutic utility in AKI. The literature to date is briefly reviewed in this article.

Original languageEnglish (US)
Pages (from-to)665-672
Number of pages8
JournalNephron
Volume144
Issue number12
DOIs
StatePublished - Dec 2020

Keywords

  • Acute kidney injury
  • Biomarker
  • Chronic kidney disease
  • FGF23
  • Klotho
  • Treatment

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)
  • Urology

Fingerprint Dive into the research topics of 'Fibroblast Growth Factor 23 and αklotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications'. Together they form a unique fingerprint.

Cite this